{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:03:36Z","timestamp":1794330216694,"version":"4.9.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paraneoplastic Lambert-Eaton myasthenic syndrome (pLEMS) is well-established in small-cell lung cancer (SCLC), but data on other malignancies are limited. We aimed to define the clinical phenotype of pLEMS in non-SCLC cancers (non-SCLC-pLEMS) relative to SCLC-associated LEMS (SCLC-pLEMS) and autoimmune LEMS (aiLEMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis was conducted to compare patients with SCLC-pLEMS, aiLEMS and non-SCLC-pLEMS from the European LEMS registry, and further non-SCLC-pLEMS cases were identified by a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The registry included 72 aiLEMS, 12 SCLC-pLEMS, and 11 non-SCLC-pLEMS patients. LEMS preceded cancer diagnosis in 33% of SCLC-pLEMS (median 2\u00a0months) and 30% of non-SCLC-pLEMS (median 15\u00a0months), was concurrent in 25% and 30% and followed tumor diagnosis in the remainder. At study enrollement, Quantitative Myasthenia Gravis (QMG) scores were higher in SCLC-pLEMS (median 12, range 1\u201324) with recent tumor therapy initiation (median 3\u00a0months), and lower in non-SCLC-pLEMS (median 6, range 0\u201319), with longer (median 12\u00a0months) or completed tumor therapy, and aiLEMS (median 5, range 0\u201323). During follow-up, QMG improved with tumor therapy, and worsened with recurrence\/progression in pLEMS groups. After completion of cancer treatment, QMG values in SCLC-pLEMS (median 6, range 0\u201319) and non-SCLC-pLEMS (median 5, range 1\u201322) were comparable to each other and to aiLEMS (median 7, range 0\u201329). Ataxia was significantly more frequent in SCLC-pLEMS (64%) and non-SCLC-pLEMS (55%) than in aiLEMS (19%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006 and\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.024). Another 115 literature-reported non-SCLC-pLEMS cases were identified (total n\u2009=\u2009126, comprising 137 tumors). Most common were non-small cell lung cancer (NSCLC) (n\u2009=\u200925, 18%), Merkel cell carcinoma (n\u2009=\u200918, 13%) and lymphoproliferative disorders (n\u2009=\u200915, 11%). In 52 literature-reported LEMS patients with outcome data, 88% partially or fully recovered after tumor therapy, leaving the paraneoplastic origin uncertain in many.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest that, beyond SCLC, other tumors can trigger pLEMS. Compared with aiLEMS, non-SCLC-pLEMS and SCLC-pLEMS showed a higher frequency of ataxia, and LEMS severity tended to reflect tumor treatment status, while disease severity becomes comparable across subtypes after cancer therapy. The frequent improvement of symptoms with tumor-directed treatment supports extended screening beyond SCLC and timely management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-025-00453-5","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:58:00Z","timestamp":1765209480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Paraneoplastic Lambert\u2013Eaton myasthenic syndrome associated with non-small cell lung cancer: data from the European LEMS registry and systematic review"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3618-429X","authenticated-orcid":false,"given":"Hannah","family":"Pre\u00dfler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Im\u00e8ne","family":"Haddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Daugherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Postila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"22","key":"453_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"VA Lennon","year":"1995","unstructured":"Lennon, V. A., Kryzer, T. J., Griesmann, G. E., O\u2019Suilleabhain, P. E., Windebank, A. J., Woppmann, A., Miljanich, G. P., & Lambert, E. H. (1995). Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. The New England Journal of Medicine, 332(22), 1467\u20131474. https:\/\/doi.org\/10.1056\/NEJM199506013322203","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"453_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/s0165-5728(00)00431-8","volume":"113","author":"M Benatar","year":"2001","unstructured":"Benatar, M., Blaes, F., Johnston, I., Wilson, K., Vincent, A., Beeson, D., & Lang, B. (2001). Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line. Journal of Neuroimmunology, 113(1), 153\u2013162. https:\/\/doi.org\/10.1016\/s0165-5728(00)00431-8","journal-title":"Journal of Neuroimmunology"},{"issue":"12","key":"453_CR3","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/s0025-6196(12)61144-6","volume":"67","author":"M Oguro-Okano","year":"1992","unstructured":"Oguro-Okano, M., Griesmann, G. E., Wieben, E. D., Slaymaker, S. J., Snutch, T. P., & Lennon, V. A. (1992). Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clinic Proceedings, 67(12), 1150\u20131159. https:\/\/doi.org\/10.1016\/s0025-6196(12)61144-6","journal-title":"Mayo Clinic Proceedings"},{"issue":"3","key":"453_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/mus.25520","volume":"56","author":"DC Abenroth","year":"2017","unstructured":"Abenroth, D. C., Smith, A. G., Greenlee, J. E., Austin, S. D., & Clardy, S. L. (2017). Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population. Muscle & Nerve, 56(3), 421\u2013426. https:\/\/doi.org\/10.1002\/mus.25520","journal-title":"Muscle & Nerve"},{"issue":"26","key":"453_CR5","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1200\/JCO.2008.17.5133","volume":"26","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer, M. J., Wirtz, P. W., Willems, L. N., van Kralingen, K. W., Smitt, P. A., & Verschuuren, J. J. (2008). Screening for small-cell lung cancer: A follow-up study of patients with Lambert-Eaton myasthenic syndrome. Journal of Clinical Oncology, 26(26), 4276\u20134281. https:\/\/doi.org\/10.1200\/JCO.2008.17.5133","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"453_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O'Neill","year":"1988","unstructured":"O\u2019Neill, J. H., Murray, N. M., & Newsom-Davis, J. (1988). The lambert-eaton myasthenic syndrome. A review of 50 cases. Brain, 111(3), 577\u2013596. https:\/\/doi.org\/10.1093\/brain\/111.3.577","journal-title":"Brain"},{"issue":"7","key":"453_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.nmd.2021.05.006","volume":"31","author":"AM Ruiter","year":"2021","unstructured":"Ruiter, A. M., Strijbos, E., de Meel, R. H. P., Lipka, A. F., Raadsheer, W. F., Tannemaat, M. R., & Verschuuren, J. (2021). Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome. Neuromuscular Disorders, 31(7), 622\u2013632. https:\/\/doi.org\/10.1016\/j.nmd.2021.05.006","journal-title":"Neuromuscular Disorders"},{"issue":"11","key":"453_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1212\/01.wnl.0000037485.56217.5f","volume":"59","author":"YK Nakao","year":"2002","unstructured":"Nakao, Y. K., Motomura, M., Fukudome, T., Fukuda, T., Shiraishi, H., Yoshimura, T., Tsujihata, M., & Eguchi, K. (2002). Seronegative Lambert-Eaton myasthenic syndrome: Study of 110 Japanese patients. Neurology, 59(11), 1773\u20131775. https:\/\/doi.org\/10.1212\/01.wnl.0000037485.56217.5f","journal-title":"Neurology"},{"issue":"11","key":"453_CR9","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1212\/wnl.54.11.2176","volume":"54","author":"RW Tim","year":"2000","unstructured":"Tim, R. W., Massey, J. M., & Sanders, D. B. (2000). Lambert-Eaton myasthenic syndrome: Electrodiagnostic findings and response to treatment. Neurology, 54(11), 2176\u20132178. https:\/\/doi.org\/10.1212\/wnl.54.11.2176","journal-title":"Neurology"},{"issue":"6","key":"453_CR10","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.athoracsur.2009.11.041","volume":"89","author":"M Morimoto","year":"2010","unstructured":"Morimoto, M., Osaki, T., Nagara, Y., Kodate, M., Motomura, M., & Murai, H. (2010). Thymoma with Lambert-Eaton myasthenic syndrome. The Annals of Thoracic Surgery, 89(6), 2001\u20132003. https:\/\/doi.org\/10.1016\/j.athoracsur.2009.11.041","journal-title":"The Annals of Thoracic Surgery"},{"issue":"2","key":"453_CR11","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2010.10.003","volume":"21","author":"R Fernandez-Torron","year":"2011","unstructured":"Fernandez-Torron, R., Arcocha, J., Lopez-Picazo, J. M., Pardo, J., Tamura, M. A., Carretero, C., & Pastor, P. (2011). Isolated dysphagia due to paraneoplastic myasthenic syndrome with anti-P\/Q-type voltage-gated calcium-channel and anti-acetylcholine receptor antibodies. Neuromuscular Disorders, 21(2), 126\u2013128. https:\/\/doi.org\/10.1016\/j.nmd.2010.10.003","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"453_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1212\/wnl.30.6.634","volume":"30","author":"M Lauritzen","year":"1980","unstructured":"Lauritzen, M., Smith, T., Fischer-Hansen, B., Sparup, J., & Olesen, J. (1980). Eaton-Lambert syndrome and malignant thymoma. Neurology, 30(6), 634\u2013638. https:\/\/doi.org\/10.1212\/wnl.30.6.634","journal-title":"Neurology"},{"issue":"3","key":"453_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/00365599509180590","volume":"29","author":"SK Agarawal","year":"1995","unstructured":"Agarawal, S. K., Birch, B. R., & Abercrombie, G. F. (1995). Adenocarcinoma of the prostate and Eaton-Lambert syndrome A previously unreported association. Scandinavian Journal of Urology and Nephrology, 29(3), 351\u2013353. https:\/\/doi.org\/10.3109\/00365599509180590","journal-title":"Scandinavian Journal of Urology and Nephrology"},{"issue":"10","key":"453_CR14","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1212\/wnl.42.10.1944","volume":"42","author":"PD Clouston","year":"1992","unstructured":"Clouston, P. D., Saper, C. B., Arbizu, T., Johnston, I., Lang, B., Newsom-Davis, J., & Posner, J. B. (1992). Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration cancer and the Lambert-Eaton myasthenic syndrome. Neurology, 42(10), 1944\u20131950. https:\/\/doi.org\/10.1212\/wnl.42.10.1944","journal-title":"Neurology"},{"issue":"2","key":"453_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0090-4295(89)90017-4","volume":"33","author":"B Tetu","year":"1989","unstructured":"Tetu, B., Ro, J. Y., Ayala, A. G., Ordonez, N. G., Logothetis, C. J., & von Eschenbach, A. C. (1989). Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome. Urology, 33(2), 148\u2013152. https:\/\/doi.org\/10.1016\/0090-4295(89)90017-4","journal-title":"Urology"},{"issue":"1","key":"453_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/S0022-5347(05)64091-8","volume":"169","author":"B Delahunt","year":"2003","unstructured":"Delahunt, B., Abernethy, D. A., Johnson, C. A., & Nacey, J. N. (2003). Prostate carcinoma and the Lambert-Eaton myasthenic syndrome. The Journal of Urology, 169(1), 278\u2013279. https:\/\/doi.org\/10.1016\/S0022-5347(05)64091-8","journal-title":"The Journal of Urology"},{"issue":"11","key":"453_CR17","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1007\/s10072-015-2315-x","volume":"36","author":"C Monteiro","year":"2015","unstructured":"Monteiro, C., Moreira, I., Lima, J. L., & Santos, E. (2015). Lambert-Eaton myasthenic syndrome and prostatic adenocarcinoma. Neurological Sciences, 36(11), 2145\u20132146. https:\/\/doi.org\/10.1007\/s10072-015-2315-x","journal-title":"Neurological Sciences"},{"key":"453_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1196\/annals.1405.030","volume":"1132","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer, M. J., & Verschuuren, J. J. (2008). Lambert-Eaton myasthenic syndrome: Tumor versus nontumor forms. Annals of the New York Academy of Sciences, 1132, 129\u2013134. https:\/\/doi.org\/10.1196\/annals.1405.030","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"6","key":"453_CR19","doi-asserted-by":"publisher","first-page":"e200260","DOI":"10.1212\/NXI.0000000000200260","volume":"11","author":"NL Ciano-Petersen","year":"2024","unstructured":"Ciano-Petersen, N. L., Muniz-Castrillo, S., Villagran-Garcia, M., Farina, A., Vogrig, A., Wucher, V., Duy, L., Birzu, C., Goncalves, D., Flabeau, O., Duwicquet, C., Benard, A., Nicole, F., Rogemond, V., Picard, G., Joubert, B., & Honnorat, J. (2024). Paraneoplastic neurologic syndromes associated with merkel cell carcinoma. Neurology Neuroimmunology & Neuroinflammation, 11(6), e200260. https:\/\/doi.org\/10.1212\/NXI.0000000000200260","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"issue":"9-10","key":"453_CR20","first-page":"574","volume":"53","author":"W Homenda","year":"2000","unstructured":"Homenda, W., & Hellmann, A. (2000). [Hodgkin\u2019s disease with systemic vasculitis and Lambert-Eaton myasthenic syndrome--case report]. Wiadomosci Lekarskie (Warsaw, Poland\u202f: 1960), 53(9\u201310), 574\u2013578.","journal-title":"Wiadomosci Lekarskie (Warsaw, Poland : 1960)"},{"issue":"7","key":"453_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/mus.880180707","volume":"18","author":"Z Argov","year":"1995","unstructured":"Argov, Z., Shapira, Y., Averbuch-Heller, L., & Wirguin, I. (1995). Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle & Nerve, 18(7), 715\u2013719. https:\/\/doi.org\/10.1002\/mus.880180707","journal-title":"Muscle & Nerve"},{"issue":"17","key":"453_CR22","first-page":"1337","volume":"59","author":"C Portha","year":"1983","unstructured":"Portha, C., Dupond, J. L., Monnier, G., Bosset, J. F., & Leconte des Floris, R. (1983). [Eaton-Lambert syndrome associated with multiple myeloma: Resolution of the neuromuscular block after chemotherapy]. La Semaine des Hopitaux, 59(17), 1337\u20131339.","journal-title":"La Semaine des Hopitaux"},{"issue":"4","key":"453_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000207574","volume":"62","author":"MA Wohl","year":"1979","unstructured":"Wohl, M. A., & Wood, J. K. (1979). Chronic myeloid leukaemia and a myasthenic syndrome. Acta Haematologica, 62(4), 214\u2013218. https:\/\/doi.org\/10.1159\/000207574","journal-title":"Acta Haematologica"},{"issue":"12","key":"453_CR24","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/00007611-198812000-00028","volume":"81","author":"JD Morrow","year":"1988","unstructured":"Morrow, J. D., Manian, F. A., Clinton, M. E., & Stein, R. S. (1988). Eaton-Lambert syndrome in a patient with acute T cell lymphocytic leukemia. Southern Medical Journal, 81(12), 1578\u20131579. https:\/\/doi.org\/10.1097\/00007611-198812000-00028","journal-title":"Southern Medical Journal"},{"issue":"5","key":"453_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.1149","volume":"11","author":"T Soma","year":"2023","unstructured":"Soma, T., Matsumoto, A., Shoji, T., & Katakura, H. (2023). Lambert-Eaton myasthenic syndrome with primary thymic marginal zone B-cell lymphoma: A case report. Respirology Case Reports, 11(5), Article e01149. https:\/\/doi.org\/10.1002\/rcr2.1149","journal-title":"Respirology Case Reports"},{"key":"453_CR26","doi-asserted-by":"publisher","first-page":"1667540","DOI":"10.3389\/fneur.2025.1667540","volume":"16","author":"B Inan","year":"2025","unstructured":"Inan, B., Ozturk, B., Ata, N., Birinci, S., Eroglu, E., Karadas, O., Tan, E., & Odabasi, Z. (2025). Epidemiological analysis of Lambert-Eaton myasthenic syndrome in Turkiye: Insights from a nationwide electronic health database. Frontiers in Neurology, 16, 1667540. https:\/\/doi.org\/10.3389\/fneur.2025.1667540","journal-title":"Frontiers in Neurology"},{"issue":"2","key":"453_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40120-015-0034-0","volume":"4","author":"R Mantegazza","year":"2015","unstructured":"Mantegazza, R., Meisel, A., Sieb, J. P., Le Masson, G., Desnuelle, C., & Essing, M. (2015). The European LEMS registry: Baseline demographics and treatment approaches. Neurology and Therapy, 4(2), 105\u2013124. https:\/\/doi.org\/10.1007\/s40120-015-0034-0","journal-title":"Neurology and Therapy"},{"issue":"3","key":"453_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40120-022-00354-8","volume":"11","author":"A Meisel","year":"2022","unstructured":"Meisel, A., Sieb, J. P., Le Masson, G., Postila, V., & Sacconi, S. (2022). The European Lambert-Eaton myasthenic syndrome registry: Long-term outcomes following symptomatic treatment. Neurology and Therapy, 11(3), 1071\u20131083. https:\/\/doi.org\/10.1007\/s40120-022-00354-8","journal-title":"Neurology and Therapy"},{"key":"453_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jneuroim.2008.05.025","volume":"201-202","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer, M. J., Wirtz, P. W., Kuks, J. B., Schelhaas, H. J., van der Kooi, A. J., Faber, C. G., van der Pol, W. L., de Visser, M., Sillevis Smitt, P. A., & Verschuuren, J. J. (2008). The Lambert-Eaton myasthenic syndrome 1988-2008: A clinical picture in 97 patients. Journal of Neuroimmunology, 201\u2013202, 153\u2013158. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.05.025","journal-title":"Journal of Neuroimmunology"},{"issue":"1","key":"453_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/jnnp.58.1.85","volume":"58","author":"M Motomura","year":"1995","unstructured":"Motomura, M., Johnston, I., Lang, B., Vincent, A., & Newsom-Davis, J. (1995). An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery, and Psychiatry, 58(1), 85\u201387. https:\/\/doi.org\/10.1136\/jnnp.58.1.85","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"4","key":"453_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/s0303-8467(02)00054-9","volume":"104","author":"PW Wirtz","year":"2002","unstructured":"Wirtz, P. W., Smallegange, T. M., Wintzen, A. R., & Verschuuren, J. J. (2002). Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: An analysis of 227 published cases. Clinical Neurology and Neurosurgery, 104(4), 359\u2013363. https:\/\/doi.org\/10.1016\/s0303-8467(02)00054-9","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"6","key":"453_CR32","doi-asserted-by":"publisher","first-page":"e16273","DOI":"10.1111\/ene.16273","volume":"31","author":"G Mangioris","year":"2024","unstructured":"Mangioris, G., Halfdanarson, T. R., Lennon, V. A., Chang, B. K., Dubey, D., Dyck, P. J. B., Flanagan, E. P., McKeon, A., Mills, J. R., Pittock, S. J., & Zekeridou, A. (2024). Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: Clinical manifestations and neural autoantibody profiles. European Journal of Neurology, 31(6), e16273. https:\/\/doi.org\/10.1111\/ene.16273","journal-title":"European Journal of Neurology"},{"issue":"6039","key":"453_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/317737a0","volume":"317","author":"A Roberts","year":"1985","unstructured":"Roberts, A., Perera, S., Lang, B., Vincent, A., & Newsom-Davis, J. (1985). Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature, 317(6039), 737\u2013739. https:\/\/doi.org\/10.1038\/317737a0","journal-title":"Nature"},{"issue":"3","key":"453_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ana.410250310","volume":"25","author":"B Lang","year":"1989","unstructured":"Lang, B., Vincent, A., Murray, N. M., & Newsom-Davis, J. (1989). Lambert-Eaton myasthenic syndrome: Immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity. Annals of Neurology, 25(3), 265\u2013271. https:\/\/doi.org\/10.1002\/ana.410250310","journal-title":"Annals of Neurology"},{"key":"453_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1752-1947-6-281","volume":"6","author":"H Arai","year":"2012","unstructured":"Arai, H., Inui, K., Hashimoto, K., Kan, O. K., Nishii, T., Kishida, H., Okudela, K., Tsuboi, M., Nozawa, A., Kaneko, T., & Masuda, M. (2012). Lung adenocarcinoma with Lambert-Eaton myasthenic syndrome indicated by voltage-gated calcium channel: A case report. Journal of Medical Case Reports, 6, 281. https:\/\/doi.org\/10.1186\/1752-1947-6-281","journal-title":"Journal of Medical Case Reports"},{"issue":"7","key":"453_CR36","doi-asserted-by":"publisher","first-page":"e0125766","DOI":"10.1371\/journal.pone.0125766","volume":"10","author":"CY Wang","year":"2015","unstructured":"Wang, C. Y., Lai, M. D., Phan, N. N., Sun, Z., & Lin, Y. C. (2015). Meta-analysis of public microarray datasets reveals voltage-gated calcium gene signatures in clinical cancer patients. PLoS ONE, 10(7), e0125766. https:\/\/doi.org\/10.1371\/journal.pone.0125766","journal-title":"PLoS ONE"},{"key":"453_CR37","unstructured":"Uhl\u00e9n M, F. L., Hallstr\u00f6m BM, et al. (oder: The Human Protein Atlas). (2024). CACNA1A in cancer - The Human Protein Atlas. https:\/\/v19.proteinatlas.org\/ENSG00000141837-CACNA1A\/pathology"},{"key":"453_CR38","doi-asserted-by":"publisher","unstructured":"Graus, F., Vogrig, A., Muniz-Castrillo, S., Antoine, J. G., Desestret, V., Dubey, D., Giometto, B., Irani, S. R., Joubert, B., Leypoldt, F., McKeon, A., Pruss, H., Psimaras, D., Thomas, L., Titulaer, M. J., Vedeler, C. A., Verschuuren, J. J., Dalmau, J., & Honnorat, J. (2021). Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm, 8(4). https:\/\/doi.org\/10.1212\/NXI.0000000000001014","DOI":"10.1212\/NXI.0000000000001014"},{"issue":"1","key":"453_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s0022-510x(96)05303-8","volume":"147","author":"M Motomura","year":"1997","unstructured":"Motomura, M., Lang, B., Johnston, I., Palace, J., Vincent, A., & Newsom-Davis, J. (1997). Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Journal of the Neurological Sciences, 147(1), 35\u201342. https:\/\/doi.org\/10.1016\/s0022-510x(96)05303-8","journal-title":"Journal of the Neurological Sciences"},{"issue":"12","key":"453_CR40","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/jnnp.2006.100594","volume":"77","author":"J Honnorat","year":"2006","unstructured":"Honnorat, J. (2006). Understanding the physiopathology of paraneoplastic and genetic cerebellar ataxia. Journal of Neurology, Neurosurgery, and Psychiatry, 77(12), 1299\u20131300. https:\/\/doi.org\/10.1136\/jnnp.2006.100594","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"453_CR41","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1212\/wnl.59.5.764","volume":"59","author":"F Graus","year":"2002","unstructured":"Graus, F., Lang, B., Pozo-Rosich, P., Saiz, A., Casamitjana, R., & Vincent, A. (2002). P\/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology, 59(5), 764\u2013766. https:\/\/doi.org\/10.1212\/wnl.59.5.764","journal-title":"Neurology"},{"issue":"Pt 6","key":"453_CR42","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","volume":"124","author":"F Graus","year":"2001","unstructured":"Graus, F., Keime-Guibert, F., Rene, R., Benyahia, B., Ribalta, T., Ascaso, C., Escaramis, G., & Delattre, J. Y. (2001). Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain, 124(Pt 6), 1138\u20131148. https:\/\/doi.org\/10.1093\/brain\/124.6.1138","journal-title":"Brain"},{"issue":"1","key":"453_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/ana.10225","volume":"52","author":"JE Greenlee","year":"2002","unstructured":"Greenlee, J. E., Steffens, J. D., Clawson, S. A., Hill, K., & Dalmau, J. (2002). Anti-Hu antibodies in Merkel cell carcinoma. Annals of Neurology, 52(1), 111\u2013115. https:\/\/doi.org\/10.1002\/ana.10225","journal-title":"Annals of Neurology"},{"issue":"6","key":"453_CR44","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1365-2559.2004.01792.x","volume":"44","author":"MC Lopez","year":"2004","unstructured":"Lopez, M. C., Pericay, C., Agusti, M., Martinez-Gallo, M., Bordes, R., & Gelpi, C. (2004). Merkel cell carcinoma associated with a paraneoplastic neurological syndrome. Histopathology, 44(6), 628\u2013629. https:\/\/doi.org\/10.1111\/j.1365-2559.2004.01792.x","journal-title":"Histopathology"},{"issue":"1-2","key":"453_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jns.2008.02.004","volume":"270","author":"PJ Lorenzoni","year":"2008","unstructured":"Lorenzoni, P. J., Scola, R. H., Lang, B., Kay, C. S., Teive, H. A., Kowacs, P. A., & Werneck, L. C. (2008). Cerebellar ataxia in non-paraneoplastic Lambert-Eaton myasthenic syndrome. Journal of the Neurological Sciences, 270(1\u20132), 194\u2013196. https:\/\/doi.org\/10.1016\/j.jns.2008.02.004","journal-title":"Journal of the Neurological Sciences"},{"issue":"1\u20132","key":"453_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jns.2013.10.031","volume":"336","author":"A Rigamonti","year":"2014","unstructured":"Rigamonti, A., Lauria, G., Stanzani, L., Mantero, V., Andreetta, F., & Salmaggi, A. (2014). Non-paraneoplastic voltage-gated calcium channels antibody-mediated cerebellar ataxia responsive to IVIG treatment. Journal of the Neurological Sciences, 336(1\u20132), 169\u2013170. https:\/\/doi.org\/10.1016\/j.jns.2013.10.031","journal-title":"Journal of the Neurological Sciences"},{"issue":"7","key":"453_CR47","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","volume":"29","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer, M. J., Maddison, P., Sont, J. K., Wirtz, P. W., Hilton-Jones, D., Klooster, R., Willcox, N., Potman, M., Sillevis Smitt, P. A., Kuks, J. B., Roep, B. O., Vincent, A., van der Maarel, S. M., van Dijk, J. G., Lang, B., & Verschuuren, J. J. (2011). Clinical DUTCH-ENGLISh Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. Journal of Clinical Oncology, 29(7), 902\u2013908. https:\/\/doi.org\/10.1200\/JCO.2010.32.0440","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"453_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1468-1331.2010.03220.x","volume":"18","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer, M. J., Soffietti, R., Dalmau, J., Gilhus, N. E., Giometto, B., Graus, F., Grisold, W., Honnorat, J., Sillevis Smitt, P. A., Tanasescu, R., Vedeler, C. A., Voltz, R., Verschuuren, J. J., European Federation of Neurological, S. (2011). Screening for tumours in paraneoplastic syndromes: Report of an EFNS task force. European Journal of Neurology, 18(1), 19-e13. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03220.x","journal-title":"European Journal of Neurology"},{"issue":"12","key":"453_CR49","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer, M. J., Lang, B., & Verschuuren, J. J. (2011). Lambert-Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies. The Lancet Neurology, 10(12), 1098\u20131107. https:\/\/doi.org\/10.1016\/S1474-4422(11)70245-9","journal-title":"The Lancet Neurology"},{"issue":"4","key":"453_CR50","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/mus.26052","volume":"57","author":"DBVCYAGACTJSRMDPTVLRKLDP SandersJuelHaratiSmithPeltierMarbur","year":"2018","unstructured":"SandersJuelHaratiSmithPeltierMarburgerLouPascuzziRichmanXieDemmelJacobusAlesJacobus, D. B. V. C. Y. A. G. A. C. T. J. S. R. M. D. P. T. V. L. R. K. L. D. P., Dapper Study, T. (2018). 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle & Nerve, 57(4), 561\u2013568. https:\/\/doi.org\/10.1002\/mus.26052","journal-title":"Muscle & Nerve"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00453-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00453-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00453-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T15:58:02Z","timestamp":1765209482000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00453-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00453-5","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All registry procedures complied with institutional and national ethics standards and the Declaration of Helsinki. Ethical approval was obtained from the respective Ethics Committees at all participating centers: Paris DRGI (CCTRIS MG\/CP010.868), Berlin (EA1\/048\/10), Hamburg (MC-278\/10), Regensburg (11\u2013103-0181), Greifswald (BB113\/10), Luebeck (11\u2013135), Kiel (B328\/11), Milan (Verbale Comitato Etico n.11), Rome ((A.199)\/C.E\/2011), Pavia (LEMS-01), Valencia (BIO-AMI-2010\u201301), Madrid (LEMS-01), Cottingham (R1697). Written informed consent was obtained from all participants. The LEMS registry protocol, patient information sheet, and informed consent form were reviewed and approved by the responsible ethics committees at participating centers in accordance with local regulations. All approvals were in place before site initiation and patient enrollment. Copies of approvals and study documents are on file with SERB SA (Brussels, Belgium).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HP and IH have no competing interests. AM received speaker\u2019s speaker or consultancy honoraria or financial research support (paid to his institution) from Alexion AstraZeneca Rare Disease, Amgen, argenx, Axunio, Desitin, Genpharm, Grifols, Hormosan, Immunovant, Johneson & Johnson, Merck, Novartis, Octapharma, Regeneron, Sanofi and UCB. He serves as member (chairmen from 2019\u20132024) of the medical advisory board of the German Myasthenia Gravis Society. VP and CD are employees of Serb Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}